Table 4.
Clinical Features and Biochemical Profile of T2D Patients According to Alleles of Met408Val (rs628031) SLC22A1/OCT1 Polymorphism in Monotherapy with Metformin
n= 83 | Reference Values | Allele G | Allele A | p-value |
---|---|---|---|---|
n (%) | – | 63 (76) | 20 (24) | |
Age (years) | – | 58.6 ± 11.8 | 55.0 ± 11.8 | 0.170 |
Sex, F/M | – | 39/24 | 14/6 | 0.600 |
Years with T2D | – | 5.3 ± 6.4 | 2.5 ± 2.7 | 0.047a |
Therapy time (years) | – | 5.0 ± 5.9 | 2.2 ± 2.1 | 0.038a |
Anthropometric | ||||
BMI (Kg/m2) | 18.5–24.9 | 29.4 ± 4.9 | 32.1 ± 8.3 | 0.426 |
Normal weight n (%) | – | 10 (16) | 2 (10) | |
Overweight n (%) | – | 15 (24) | 10 (50) | 0.215 |
Obesity n (%) | – | 22 (35) | 8 (40) | |
Total body fat (%) | M: 12–20 F: 20–30 | 34.3 ± 7.9 | 36.1 ± 8.5 | 0.476 |
WC (cm) | M:<90 F:<80 | 99.3 ± 11.9 | 106.2 ± 20.0 | 0.567 |
Glycemic profile | ||||
Glucose (mg/dL) | < 110 | 127 ± 43.2 | 124 ± 43.7 | 0.454 |
HbA1c (%) | < 6.5 | 6.6 ± 1.3 | 6.7 ± 1.9 | 0.496 |
Glyc Ctrl (%HbA1c) | <7.0 | 51 (81) | 15 (75) | 1.000 |
TyG index (ratio) | < 8.31 | 9.0 ± 0.5 | 8.9 ± 0.5 | 0.532 |
I.R. (TyG index) | - | 58 (92.1) | 19 (95.0) | 0.568 |
Lipid Profile | ||||
TC (mg/dL) | < 200 | 176 ± 30.8 | 174 ± 31.9 | 0.717 |
TG (mg/dL) | < 150 | 143 ± 63.3 | 132 ± 40.3 | 0.862 |
HDL-c (mg/dL) | >50 | 49 ± 11.1 | 46 ± 9.9 | 0.696 |
Non-HDL-c (mg/dL) | <130 | 127 ± 29.6 | 128 ± 28.7 | 0.949 |
LDL-c (mg/dL) | <100 | 100 ± 26.8 | 102 ± 23.0 | 0.746 |
Notes: Values are presented as mean ± standard deviations, frequencies, and percentages. aThe t-student test was the statistical approach, p<0.05.
Abbreviations: T2D, Type 2 Diabetes; F, Female; M, Male; BMI, Body Mass Index; WC, Waist Circumference; HbA1c, Glycated hemoglobin; TyG index, Triglyceride-Glucose index; I.R, Insulin Resistance; Glyc Ctrl, Glycemic control; TC, Total-cholesterol; TG, Triglycerides; HDL-c, High-density lipoprotein cholesterol; Non-HDL-c, Non-high-density lipoprotein cholesterol; LDL-c, Low-density lipoprotein cholesterol; mg, milligrams; dL, deciliters.